254 related articles for article (PubMed ID: 6391404)
1. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
Burnakis TG; Mioduch HJ
Arch Intern Med; 1984 Dec; 144(12):2371-2. PubMed ID: 6391404
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
3. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic.
Mooser V; Waeber G; Bidiville J; Waeber B; Nussberger J; Brunner HR
J Clin Hypertens; 1987 Dec; 3(4):510-3. PubMed ID: 2839627
[TBL] [Abstract][Full Text] [Related]
4. Prediction of hyperkalemia associated with prolonged treatment with captopril by glucose-induced acute serum potassium changes.
Radó JP
Exp Clin Endocrinol; 1984 Oct; 84(2):143-7. PubMed ID: 6396097
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
Fuster D; Frey FJ; Ferrari P
Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
[TBL] [Abstract][Full Text] [Related]
7. Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. Xamoterol in Severe Heart Failure Study Group.
Bergler-Klein J; Sochor H; Pouleur H; Pacher R; Porenta G; Glogar D
J Cardiovasc Pharmacol; 1994 Aug; 24(2):194-8. PubMed ID: 7526050
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.
Chan TY; Critchley JA
Drug Saf; 1992; 7(2):159-61. PubMed ID: 1605901
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of captopril and spironolactone for refractory congestive heart failure.
Han YL; Tong M; Jing QM; Hu XL; Liu JQ
Chin Med J (Engl); 1994 Sep; 107(9):688-92. PubMed ID: 7805462
[TBL] [Abstract][Full Text] [Related]
10. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
Shah KB; Rao K; Sawyer R; Gottlieb SS
J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
[TBL] [Abstract][Full Text] [Related]
11. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
12. Interplay of various factors in glucose-induced hyperkalemia during captopril treatment.
Radó JP; Gercsák G; Bános C
Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):69-76. PubMed ID: 3514489
[TBL] [Abstract][Full Text] [Related]
13. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.
Textor SC; Bravo EL; Fouad FM; Tarazi RC
Am J Med; 1982 Nov; 73(5):719-25. PubMed ID: 6291388
[TBL] [Abstract][Full Text] [Related]
14. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
[TBL] [Abstract][Full Text] [Related]
15. Glucose-induced hyperkalemia developing in the upright position in captopril-treated hypertensives.
Radó JP; Bános C; Gercsák G; Molnár Z; Pató E; Csabuda M
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):161-4. PubMed ID: 6755590
[TBL] [Abstract][Full Text] [Related]
16. Hypokalemia during the treatment of arterial hypertension with diuretics.
Lemieux G; Beauchemin M; Vinay P; Gougoux A
Can Med Assoc J; 1980 Apr; 122(8):905-7. PubMed ID: 7370875
[TBL] [Abstract][Full Text] [Related]
17. [Severe electrolyte disorders during the therapy of heart failure with the therapy of heart failure with the ACE-inhibitor enalapril].
Hess B; Keusch G; Neftel K; Margelist F; Bansky G
Schweiz Med Wochenschr; 1986 Sep; 116(39):1331-6. PubMed ID: 3022372
[TBL] [Abstract][Full Text] [Related]
18. Deterioration of renal function and hyperkalemia in hypertensive patients with impaired renal function during captopril administration.
Kodama K; Morotomi Y; Kida O; Higa T; Someya N; Kondo K; Tanaka K
Nihon Jinzo Gakkai Shi; 1985 Mar; 27(3):327-35. PubMed ID: 3894730
[No Abstract] [Full Text] [Related]
19. Captopril in patients with terminal cardiac failure.
Nicholls MG; Ikram H; Hull FT
N Z Med J; 1982 Oct; 95(718):736-8. PubMed ID: 6755319
[TBL] [Abstract][Full Text] [Related]
20. [Effect of captopril in essential hypertension (author's transl)].
Mimran A; Targhetta R; Laroche B
Nouv Presse Med; 1981 Apr; 10(19):1579-82. PubMed ID: 7025849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
